Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enrolment halted in key Avastin Phase III adjuvant breast cancer trial

This article was originally published in Scrip

Executive Summary

Enrolment in a key pivotal Phase III trial testing Roche (Genentech)'s Avastin (bevacizumab) in adjuvant breast cancer has been suspended because the threshold of numbers of cases of congestive heart failure (CHF) had been met, highlighting the higher safety hurdle that needs to be demonstrated in the adjuvant disease setting. The trial's Data Safety Monitoring Board (DSMB) will decide if and when to resume enrolment, which will be a major decision for Avastin’s future in adjuvant breast cancer.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC004804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel